FDA clears pancreatic cancer breakthrough, but insurance lags behind
FDA approved Revolution Medicines’ pancreatic cancer drug Rasonque last month, a potential median-survival boost, but the closure of expanded-access programs and the slow pace of insurer coverage created a gap for patients like Juan Solano. The drug carries a near-$40,000 monthly price, and while patient-access programs and later insurer actions provided some relief, many families face a confusing, time-consuming path to obtain treatment after FDA clearance, underscoring a broader need for policy and payer systems to expedite coverage after approvals.
